Shandong Xinhua Pharmaceutical Company Limited has recently received the Notice of Approval of Supplementary Drug Application from the National Medical Products Administration in relation to the approval of Naloxone Hydrochloride Injection, which has passed the Consistency of Quality and Efficacy Evaluation for Generic Drugs. Relevant information is now announced as follows: Drug name: Naloxone Hydrochloride Injection; Dosage form: Injection; Specifications: 1ml:0.4mg, 1ml:1mg, 2ml:2mg; Drug category: Prescription Drugs; Registration category: Chemicals; Applicant: Shandong Xinhua Pharmaceutical Company Limited; Application matter: Consistency of Quality and Efficacy Evaluation for Generic Drugs; Approval number: CYHB2350313, CYHB2350315, CYHB2350314; Original drug approval number: Guoyao Zhunzi H20055761,Guoyao Zhunzi H20055762, Guoyao Zhunzi H20055763; Notification number: 2024B02422, 2024B02421,2024B02420. Review conclusion: Passed the consistency of quality and efficacy evaluation for generic drugs.